Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer

Objectives: This study will compare the incidence of major adverse cardiovascular events (MACEs) with androgen deprivation therapy (ADT) among men with advanced prostate cancer who are being treated with a gonadotropin-releasing hormone (GnRH) antagonist versus a GnRH agonist. Background: Treatment...

Full description

Bibliographic Details
Main Authors: Chiara Melloni, MD, MHS, Susan F. Slovin, MD, PhD, Allan Blemings, MS, Shaun G. Goodman, MD, MSc, Christopher P. Evans, MD, Jan Nilsson, MD, Deepak L. Bhatt, MD, MPH, Konstantin Zubovskiy, MD, Tine K. Olesen, MS, MBA, Klaus Dugi, MD, Noel W. Clarke, MBBS, ChM, Celestia S. Higano, MD, Matthew T. Roe, MD, MHS
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:JACC. CardioOncology
Subjects:
cardiovascular safety
outcomes
prostate cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087320300053

Similar Items

Similar Items